Cited by 377Parkinson's Disease Mechanisms and TreatmentsStatistical Methods in EpidemiologyDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Risk tables for parkinsonism and Parkinson’s disease

Elbaz, Alexis, Bower, James H, Maraganore, Demetrius M, McDonnell, Shannon K, Peterson, Brett J, Ahlskog, J.Eric, Schaid, Daniel J, Rocca, Walter A·2002·Journal of Clinical Epidemiology

DOI 10.1016/s0895-4356(01)00425-5

Open this paper in CoChat — free account

Abstract

We applied the incidence rates of parkinsonism and Parkinson's disease (PD) from Olmsted County, MN (1976-1990) to a hypothetical cohort undergoing the mortality rates observed in Minnesota, and computed the lifetime risk and the remaining lifetime risk of developing parkinsonism and PD. These risks were compared to cumulative incidences that do not take competing risks of death into account. The lifetime risk of developing parkinsonism from birth was 4.4% for men and 3.7% for women (ratio = 1.2). The corresponding risk of developing PD was 2.0% for men and 1.3% for women (ratio = 1.5). Because of the opposite effect of higher incidence and higher mortality rates in men, the lifetime risks were only slightly higher in men than in women. Lifetime cumulative incidences were consistently higher than lifetime risks; this difference was more pronounced in men and in older subjects. Lifetime risk estimates are useful in clinical practice, epidemiologic research, and public health.

Integrity signals

Registry

Crossref · 10.1016/s0895-4356(01)00425-5

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

History of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease.
de Rijk, M. C., Tzourio, C., Breteler, M. M., Dartigues, J. F., Amaducci, L., Lopez-Pousa, S., Manubens-Bertran, J. M., Alperovitch, A., & Rocca, W. A. (1997) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.1.10 · Cited by 833
The Patient Record in Epidemiology
Kurland, L. T., & Molgaard, C. A. (1981) · Scientific American · doi:10.1038/scientificamerican1081-54 · Cited by 780
The Lifetime Risk of Developing Breast Cancer
Feuer, E. J., Wun, L., Boring, C. C., Flanders, W. D., Timmel, M. J., & Tong, T. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.11.892 · Cited by 640
Parkinson’s disease and parkinsonism in a longitudinal study: Two-fold higher incidence in men
Baldereschi, M., Di Carlo, A., Rocca, W. A., Vanni, P., Maggi, S., Perissinotto, E., Grigoletto, F., Amaducci, L., & Inzitari, D. (2000) · Neurology · doi:10.1212/wnl.55.9.1358 · Cited by 526
Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990
Bower, J. H., Maraganore, D. M., McDonnell, S. K., & Rocca, W. A. (1999) · Neurology · doi:10.1212/wnl.52.6.1214 · Cited by 509
Lifetime risk of dementia and Alzheimer's disease: The impact of mortality on risk estimates in the Framingham Study
Seshadri, S., Wolf, P. A., Beiser, A., Au, R., McNulty, K., White, R., & D'Agostino, R. B. (1997) · Neurology · doi:10.1212/wnl.49.6.1498 · Cited by 489
Incidence and Risk of Dementia: The Rotterdam study
Ott, A., Breteler, M. M. B., Harskamp, F. V., Stijnen, T., & Hofman, A. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009489 · Cited by 455
The Frequency of Idiopathic Parkinson's Disease by Age, Ethnic Group, and Sex in Northern Manhattan, 1988–1993
Mayeux, R. P., Marder, K. S., COTE, L. J., Denaro, J. E., Hemenegildo, N., Mejia‐Santana, H., Tang, M., Lantigua, R., Wilder, D., Gurland, B. J., et al. (1995) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117721 · Cited by 387
Risk of Parkinson's disease among first-degree relatives
Marder, K. S., Tang, M., Mejía, H., Alfaro, B., Cote, L. J., Louis, E. K. S., Groves, J. T., & Mayeux, R. P. (1996) · Neurology · doi:10.1212/wnl.47.1.155 · Cited by 248

Show all 21 references

Sorted by citations

Items 101–200 of 377

Implications for Estrogens in Parkinson's Disease
Ragonese, P., D’Amelio, M., & Savettieri, G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1386.004 · Cited by 63
The co‐occurrence of early onset Parkinson disease and 22q11.2 deletion syndrome
Zaleski, C. A., Bassett, A. S., Tam, K., Shugar, A. L., Chow, E. W. C., & McPherson, E. W. (2009) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.32650 · Cited by 60
Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database
Hurault‐Delarue, C., Montastruc, J., Beau, A., Lacroix, I., & Damase‐Michel, C. (2014) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-014-3210-z · Cited by 60
Neuroimmune and Inflammatory Signals in Complex Disorders of the Central Nervous System
Liberman, A. C., Trías, E., Chagas, L. D. S., Trindade, P., Pereira, M. D. S., Refojo, D., Hedin‐Pereira, C., & Serfaty, C. A. (2018) · NeuroImmunoModulation · doi:10.1159/000494761 · Cited by 62
Genetic susceptibility testing for neurodegenerative diseases: Ethical and practice issues
Roberts, J. S., & Uhlmann, W. R. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.02.005 · Cited by 62
Gender/Sex Differences in the Association of Mild Behavioral Impairment with Cognitive Aging
Wolfová, K., Creese, B., Aarsland, D., Ismail, Z., Corbett, A., Ballard, C. G., Hampshire, A., & Čermáková, P. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220040 · Cited by 60
Classification of Parkinson’s disease utilizing multi-edit nearest-neighbor and ensemble learning algorithms with speech samples
Zhang, H., Yang, L., Liu, Y., Wang, P., Yin, J., Li, Y., Qiu, M., Zhu, X., & Yan, F. (2016) · BioMedical Engineering OnLine · doi:10.1186/s12938-016-0242-6 · Cited by 58
Multifunctional role of natural products for the treatment of Parkinson’s disease: At a glance
Rahman, M. M., Wang, X., Islam, M. R., Akash, S., Supti, F. A., Mitu, M. I., Harun-Or-Rashid, M., Aktar, M. N., Kali, M. S. K., Jahan, F. I., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.976385 · Cited by 60
Sex Differences in Medium Spiny Neuron Excitability and Glutamatergic Synaptic Input: Heterogeneity Across Striatal Regions and Evidence for Estradiol-Dependent Sexual Differentiation
Cao, J., Willett, J. A., Dorris, D. M., & Meitzen, J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00173 · Cited by 61
The development of inhibitors of leucine‐rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play
Azeggagh, S., & Berwick, D. C. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15575 · Cited by 57
Sex Differences in Cardiovascular Risk Factors for Dementia
Kim, M., Kim, K., Hong, C. H., Lee, S. Y., & Jung, Y.-S. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2018.159 · Cited by 60
Parkinson's Disease: Risk Factor Modification and Prevention
Rajan, S. M., & Kaas, B. M. (2022) · Seminars in Neurology · doi:10.1055/s-0042-1758780 · Cited by 58
Plasma urate and risk of Parkinson's disease: A mendelian randomization study
Kobylecki, C. J., Nordestgaard, B. G., & Afzal, S. (2018) · Annals of Neurology · doi:10.1002/ana.25292 · Cited by 55
The Impact of Dysphagia Therapy on Quality of Life in Patients with Parkinson's Disease as Measured by the Swallowing Quality of Life Questionnaire (SWALQOL)
Ayres, A. J., Jotz, G. P., Rieder, C. R. D. M., Schuh, A. F. S., & Olchik, M. R. (2016) · International Archives of Otorhinolaryngology · doi:10.1055/s-0036-1582450 · Cited by 53
Manganese-Induced Parkinsonism: Evidence from Epidemiological and Experimental Studies
Lucchini, R. G., & Tieu, K. (2023) · Biomolecules · doi:10.3390/biom13081190 · Cited by 53
Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease
Stack, E. C., Ferro, J. L., Kim, J.-H., Signore, S. J. D., Goodrich, S., Matson, S. A., Hunt, B. B., Cormier, K., Smith, K., Matson, W. R., et al. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2007.12.006 · Cited by 53
Contributions of VPS35 Mutations to Parkinson’s Disease
Rahman, A. A., & Morrison, B. E. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.01.006 · Cited by 55
Accurate telemonitoring of Parkinson's disease diagnosis using robust inference system
Mandal, I., & Sairam, N. (2012) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2012.10.006 · Cited by 51
Neuronal Oxidative Stress Promotes α-Synuclein Aggregation In Vivo
Won, S. J., Fong, R., Butler, N. J. M., Sanchez, J., Zhang, Y., Wong, C., Nzoutchoum, O. T., Huynh, A., Pan, J., & Swanson, R. A. (2022) · Antioxidants · doi:10.3390/antiox11122466 · Cited by 49
Biographic forecasting: bridging the micro-macro gap in population forecasting
Willekens, F. (2005) · Data Archiving and Networked Services (DANS) · Cited by 49
Epidemiologie und Ursachen der Parkinson-Erkrankung
Lill, C. M., & Klein, C. (2017) · Der Nervenarzt · doi:10.1007/s00115-017-0288-0 · Cited by 47
Novel automated PD detection system using aspirin pattern with EEG signals
Barua, P. D., Doğan, Ş., Tuncer, T., Baygin, M., & Acharya, U. R. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104841 · Cited by 45
Genetic factors involved in the pathogenesis of Parkinson's disease
Lee, F. J. S., & Liu, F. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.02.001 · Cited by 43
Parkinson Disease Overview
Cook, L. P., Schulze, J., Farlow, J. L., Pankratz, N., Wojcieszek, J., & Foroud, T. (2014) · Europe PMC (PubMed Central) · Cited by 45
Implications of metal exposure and liver function in Parkinsonian patients resident in the vicinities of ferroalloy plants
Squitti, R., Gorgone, G., Panetta, V., Lucchini, R. G., Bucossi, S., Albini, E., Alessio, L., Alberici, A., Melgari, J.-M., Benussi, L., et al. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0283-0 · Cited by 44
Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson’s Disease
Latt, M. D., Lewis, S. J. G., Zekry, O., & Fung, V. S. C. (2019) · Drugs & Aging · doi:10.1007/s40266-018-0629-0 · Cited by 50
Medication Therapy Management Service for Patients with Parkinson’s Disease: A Before-and-After Study
Foppa, A. A., Chemello, C., Vargas-Peláez, C. M., & Farías, M. R. (2016) · Neurology and Therapy · doi:10.1007/s40120-016-0046-4 · Cited by 43
Cardiac sympathetic denervation predicts PD in at-risk individuals
Goldstein, D. S., Holmes, C. S., Lopez, G. J., Wu, T., & Sharabi, Y. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.10.003 · Cited by 43
Vesicular glutamate transporter modulates sex differences in dopamine neuron vulnerability to age‐related neurodegeneration
Buck, S. A., Steinkellner, T., Aslanoglou, D., Villeneuve, M., Bhatte, S. H., Childers, V. C., Rubin, S. A., Miranda, B. R. D., O’Leary, E. I., Neureiter, E. G., et al. (2021) · Aging Cell · doi:10.1111/acel.13365 · Cited by 45
Incidence and mortality of Parkinson’s disease in older Canadians
Jones, C., Martin, W. R. W., Wieler, M., King-Jesso, P., & Voaklander, D. C. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.11.018 · Cited by 42
Opposed Effects of Dityrosine Formation in Soluble and Aggregated α-Synuclein on Fibril Growth
Wördehoff, M. M., Shaykhalishahi, H., Groß, L., Gremer, L., Stoldt, M., Buell, A. K., Willbold, D., & Hoyer, W. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.09.005 · Cited by 42
Developmental exposure to the organochlorine pesticide dieldrin causes male-specific exacerbation of α-synuclein-preformed fibril-induced toxicity and motor deficits
Gezer, A. O., Kochmanski, J. J., VanOeveren, S., Cole-Strauss, A., Kemp, C. J., Patterson, J. R., Miller, K. M., Kuhn, N. C., Herman, D. E., McIntire, A., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104947 · Cited by 45
Mortality in Levodopa-Treated Parkinson's Disease
Morgan, J. C., Currie, L. J., Harrison, M. B., Bennett, J. P., Trugman, J. M., & Wooten, G. F. (2014) · Parkinson s Disease · doi:10.1155/2014/426976 · Cited by 42
Common variants in PARK loci and related genes and Parkinson's disease
Chung, S. J., Armasu, S. M., Biernacka, J. M., Lesnick, T. G., Rider, D. N., Lincoln, S., Soto‐Ortolaza, A. I., Farrer, M. J., Cunningham, J. M., Rocca, W. A., et al. (2010) · Movement Disorders · doi:10.1002/mds.23376 · Cited by 42
Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease
Blauwendraat, C., Kia, D. A., Pihlstrøm, L., Gan‐Or, Z., Lesage, S., Gibbs, J. R., Ding, J., Alcalay, R. N., Hassin‐Baer, S., Pittman, A. M., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.012 · Cited by 40
Neurosteroid Metabolites of Gonadal Steroid Hormones in Neuroprotection: Implications for Sex Differences in Neurodegenerative Disease
Mendell, A. L., & MacLusky, N. J. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00359 · Cited by 46
Sex influences in neurological disorders: case studies and perspectives
Clayton, J. A. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.4/jclayton · Cited by 39
Direct medical costs associated with Parkinson's disease: A population‐based study
Leibson, C. L., Long, K. H., Maraganore, D. M., Bower, J. H., Ransom, J. E., O’Brien, P. C., & Rocca, W. A. (2006) · Movement Disorders · doi:10.1002/mds.21075 · Cited by 39
Female reproductive factors and the risk of Parkinson’s disease: a nationwide cohort study
Yoo, J. E., Shin, D. W., Jang, W., Han, K., Kim, D., Won, H., & Park, H. S. (2020) · European Journal of Epidemiology · doi:10.1007/s10654-020-00672-x · Cited by 38
Clustering of Parkinson Disease
Kumar, A., Calne, S. M., Schulzer, M., Mak, E., Wszołek, Z. K., van Netten, C., Tsui, J. K. C., Stoessl, A. J., & Calne, D. B. (2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1057 · Cited by 38
Employment as a Welder and Parkinson Disease Among Heavy Equipment Manufacturing Workers
Marsh, G. M., & Gula, M. J. (2006) · Journal of Occupational and Environmental Medicine · doi:10.1097/01.jom.0000232547.74802.d8 · Cited by 37
Differences in brain aging between sexes in Parkinson’s disease
Beheshti, I., Booth, S., & Ko, J. H. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00646-w · Cited by 38
Wearable multimodal sensors for evaluation of patients with Parkinson disease
Oung, Q. W., Hariharan, M., Lee, H. L., Basah, S. N., Sarillee, M., & Lee, C. H. (2015) · IEEE International Conference on Control System, Computing and Engineering · doi:10.1109/iccsce.2015.7482196 · Cited by 36
Early-onset Parkinsonian behaviors in female Pink1-/- rats
Marquis, J. M., Lettenberger, S. E., & Kelm‐Nelson, C. A. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112175 · Cited by 34
Supplementation of probiotic Bifidobacterium breve Bif11 reverses neurobehavioural deficits, inflammatory changes and oxidative stress in Parkinson's disease model
Valvaikar, S., Vaidya, B., Sharma, S., Bishnoi, M., Kondepudi, K. K., & Sharma, S. S. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105691 · Cited by 35
Modulation of gut microbiome in the treatment of neurodegenerative diseases: A systematic review
Mincic, A. M., Antal, M., Filip, L. A., & Miere, D. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.05.036 · Cited by 41
Comparison of Risk Factor Profiles in Incidental Lewy Body Disease and Parkinson Disease
Frigerio, R., Fujishiro, H., Maraganore, D. M., Klos, K. J., DelleDonne, A., Heckman, M. G., Crook, J. E., Josephs, K. A., Parisi, J. E., Boeve, B. F., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.170 · Cited by 35
Rare variants in LRRK1 and Parkinson's disease
Schulte, E. C., Ellwanger, D. C., Dihanich, S., Manzoni, C., Stangl, K., Schormair, B., Graf, E., Eck, S. H., Mollenhauer, B., Haubenberger, D., et al. (2013) · Neurogenetics · doi:10.1007/s10048-013-0383-8 · Cited by 32
Polymorphisms of DRD2 and DRD3 genes and Parkinson’s disease: A meta-analysis
Dai, D., Wang, Y., Wang, L., Li, J., Ma, Q., TAO, J., Zhou, X., Zhou, H., Jiang, Y., Pan, G., et al. (2014) · Biomedical Reports · doi:10.3892/br.2014.220 · Cited by 33
Metal attenuating therapies in neurodegenerative disease
Mot, A. I., Wedd, A. G., Sinclair, L., Brown, D. R., Collins, S. J., & Brazier, M. W. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.170 · Cited by 32
Prosodic Improvement in Persons with Parkinson Disease Receiving SPEAK OUT!® Voice Therapy
Boutsen, F. R., Park, E., Dvorak, J., & Cid, C. (2018) · Folia Phoniatrica et Logopaedica · doi:10.1159/000488875 · Cited by 32
The risk of hip and non-vertebral fractures in patients with Parkinson's disease and parkinsonism: A systematic review and meta-analysis
Schini, M., Vilaça, T., Poku, E. N., Harnan, S., Sutton, A., Allen, I. E., Cummings, S. R., & Eastell, R. (2019) · Bone · doi:10.1016/j.bone.2019.115173 · Cited by 31
A review of ropinirole prolonged release in Parkinson’s disease
Pahwa, R., & Lyons (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s3358 · Cited by 31
Methamphetamine and heightened risk for early-onset stroke and Parkinson's disease: A review
Lappin, J., & Darke, S. G. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113793 · Cited by 30
LRRK2 G2019S mutation: frequency and haplotype data in South African Parkinson’s disease patients
Bardien, S., Marsberg, A., Keyser, R. J., Lombard, D., Lesage, S., Brice, A., & Carr, J. A. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0423-6 · Cited by 30
The Gender-Biased Effects of Intranasal MPTP Administration on Anhedonic- and Depressive-Like Behaviors in C57BL/6 Mice: the Role of Neurotrophic Factors
Schamne, M. G., Mack, J. M., Moretti, M., MATHEUS, F. C., Walz, R., Lanfumey, L., & Prediger, R. D. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9912-4 · Cited by 28
Goal Setting for Cognitive Rehabilitation in Mild to Moderate Parkinson’s Disease Dementia and Dementia with Lewy Bodies
Watermeyer, T., Hindle, J. V., Roberts, J., Lawrence, C. L., Martyr, A., Lloyd‐Williams, H., Brand, A., Gutting, P., Hoare, Z., Edwards, R. T., et al. (2016) · Parkinson s Disease · doi:10.1155/2016/8285041 · Cited by 28
Dual-task training to improve cognitive impairment and walking function in Parkinson's disease patients: A brief review
Zheng, Y., Meng, Z., Xiao, Z. Q., & Liang, Z. (2021) · Sports Medicine and Health Science · doi:10.1016/j.smhs.2021.10.003 · Cited by 28
Myotubularin-related phosphatase 5 is a critical determinant of autophagy in neurons
Chua, J. P., Bedi, K., Paulsen, M. T., Ljungman, M. E., Tank, E. M. H., Kim, E. S., McBride, J. P., Colon, J., Ward, M. E., Weisman, L. S., et al. (2022) · Current Biology · doi:10.1016/j.cub.2022.04.053 · Cited by 28
Variants in estrogen‐related genes and risk of Parkinson's disease
Chung, S. J., Armasu, S. M., Biernacka, J. M., Lesnick, T. G., Rider, D. N., Cunningham, J. M., & Maraganore, D. M. (2011) · Movement Disorders · doi:10.1002/mds.23604 · Cited by 27
Serum Growth Differentiation Factor 15 in Parkinson Disease
Yao, X., Wang, D., Zhang, L., Wang, L., Zhao, Z., Chen, S., Wang, X., Yue, T., & Liu, Y. (2017) · Neurodegenerative Diseases · doi:10.1159/000477349 · Cited by 27
Overall and Disease Related Mortality in Parkinson’s Disease – a Longitudinal Cohort Study
Hoogland, J., Post, B., & de Bie, R. M. A. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191652 · Cited by 27
Current status and future directions of clinical applications using iPS cells—focus on Japan
Tsujimoto, H., & Osafune, K. (2021) · FEBS Journal · doi:10.1111/febs.16162 · Cited by 25
White matter hyperintensities and smaller cortical thickness are associated with neuropsychiatric symptoms in neurodegenerative and cerebrovascular diseases
Ozzoude, M., Varriano, B. M., Beaton, D., Ramirez, J., Adamo, S. M., Holmes, M. F., Scott, C. J. M., Gao, F., Sunderland, K. M., McLaughlin, P. M., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01257-y · Cited by 26
NADPH Oxidase Mediates Membrane Androgen Receptor–Induced Neurodegeneration
Tenkorang, M. A. A., Duong, P., & Cunningham, R. L. (2019) · Endocrinology · doi:10.1210/en.2018-01079 · Cited by 26
Race and ethnicity matter! Moving Parkinson’s risk research towards diversity and inclusiveness
Siddiqi, S., Ortiz, Z., Simard, S., Li, J., Lawrence, K., Redmond, M. L., Tomlinson, J. J., Schlossmacher, M. G., & Salmaso, N. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00891-7 · Cited by 24
Association mapping of the PARK10 region for Parkinson's disease susceptibility genes
Wan, J. Y., Edwards, K. L., Hutter, C. M., Mata, I. F., Samii, A., Roberts, J. W., Agarwal, P., Checkoway, H., Farin, F. M., Yearout, D., et al. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.10.001 · Cited by 24
Neurotoxicity of Vanadium
Ngwa, H. A., Ay, M., Jin, H., Anantharam, V., Kanthasamy, A., & Kanthasamy, A. G. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-60189-2_14 · Cited by 24
A new outlier detection method based on convex optimization: application to diagnosis of Parkinson’s disease
Taylan, P., Yerlikaya–Özkurt, F., Uçak, B. B., & Weber, G. (2020) · Journal of Applied Statistics · doi:10.1080/02664763.2020.1864815 · Cited by 23
Robust Voice Feature Selection Using Interval Type-2 Fuzzy AHP for Automated Diagnosis of Parkinson's Disease
Azadi, H., Akbarzadeh-T, M.-R., Kobravi, H., & Shoeibi, A. (2021) · IEEE/ACM Transactions on Audio Speech and Language Processing · doi:10.1109/taslp.2021.3097215 · Cited by 24
Dysmetabolism and Neurodegeneration: Trick or Treat?
Capucho, A. M., Chegão, A., Martins, F. O., Miranda, H. V., & Conde, S. V. (2022) · Nutrients · doi:10.3390/nu14071425 · Cited by 26
Formulations of hormone therapy and risk of Parkinson's disease
Lundin, J. I., Ton, T. G. N., LaCroix, A. Z., Longstreth, W. T., Franklin, G. M., Swanson, P. D., Smith‐Weller, T., Racette, B. A., & Checkoway, H. (2014) · Movement Disorders · doi:10.1002/mds.26037 · Cited by 26
The Impact of Mitochondrial DNA and Nuclear Genes Related to Mitochondrial Functioning on the Risk of Parkinson’s Disease
Gawęda-Walerych, K., & Żekanowski, C. (2014) · Current Genomics · doi:10.2174/1389202914666131210211033 · Cited by 23
Sexual dimorphism in Parkinson’s disease: differences in clinical manifestations, quality of life and psychosocial functioning between males and females
Farhadi, F., Vosoughi, K., Shahidi, G. A., Delbari, A., Lökk, J., & Fereshtehnejad, S. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s124984 · Cited by 24
Gender Differences of Dementia in Response to Intensive Self-Administered Transcranial and Intraocular Near-Infrared Stimulation
Qi, X., Nizamutdinov, D., Berman, M. H., Dougal, G., Chazot, P. L., Wu, E., Stevens, A. B., Yi, S. S., & Huang, J. H. (2021) · Cureus · doi:10.7759/cureus.16188 · Cited by 22
Implicitly-learned spatial attention is unimpaired in patients with Parkinson's disease
Sisk, C. A., Twedell, E. L., Koutstaal, W., Cooper, S. E., & Jiang, Y. V. (2018) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2018.07.030 · Cited by 23
Sex differences in neurological disorders: Insights from ischemic stroke, Parkinson’s disease, and multiple sclerosis
Kaufhold, C. J., Mani, K. K., Akbari, Z., & Sohrabji, F. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.06.026 · Cited by 21
The use of rhythm in rehabilitation for patients with movement disorders
Bella, S. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817422-7.00015-8 · Cited by 28
Developmental exposure to the Parkinson’s disease-associated organochlorine pesticide dieldrin alters dopamine neurotransmission in α-synuclein pre-formed fibril (PFF)-injected mice
Boyd, S., Kuhn, N. C., Patterson, J. R., Stoll, A. C., Zimmerman, S. A., Kolanowski, M. R., Neubecker, J. J., Luk, K. C., Ramsson, E. S., Sortwell, C. E., et al. (2023) · Toxicological Sciences · doi:10.1093/toxsci/kfad086 · Cited by 21
Objective Evaluation of Freezing of Gait in Patients with Parkinson's Disease through Machine Learning Approaches
Oung, Q. W., Basah, S. N., Muthusamy, H., Vijean, V., Lee, H. L., Khairunizam, W., Shahriman, A. B., Razlan, Z. M., & Ibrahim, Z. (2018) · International Conference on Computational Approach in Smart Systems Design and Applications (ICASSDA) · doi:10.1109/icassda.2018.8477606 · Cited by 21
Incidence of Parkinson’s disease in French women from the E3N cohort study over 27 years of follow-up
Canonico, M., Artaud, F., Degaey, I., Moisan, F., Kabore, R., Portugal, B., Nguyen, T. T. H., Pesce, G., Boutron‐Ruault, M., Roze, E. F., et al. (2022) · European Journal of Epidemiology · doi:10.1007/s10654-022-00851-y · Cited by 21
Conjugal parkinsonism – Clinical, pathology and genetic study. No evidence of person-to-person transmission
Rajput, A. H., Ferguson, L. W., Robinson, C. A., Guella, I., Farrer, M. J., & Rajput, A. H. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.07.011 · Cited by 20
A Critical Analysis of Quercetin as the Attractive Target for the Treatment of Parkinson's Disease
Açıkara, Ö. B., Karatoprak, G. Ş., Yücel, Ç., Akkol, E. K., Sobarzo‐Sánchez, E., Khayatkashani, M., Kamal, M. A., & Kashani, H. R. K. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666211206122407 · Cited by 20
Disease-directed engineering for physiology-driven treatment interventions in neurological disorders
Wood, T. R., & Nance, E. A. (2019) · APL Bioengineering · doi:10.1063/1.5117299 · Cited by 21
Genetic variation and pesticide exposure influence blood DNA methylation signatures in females with early-stage Parkinson’s disease
Schaffner, S. L., Casazza, W., Artaud, F., Konwar, C., Merrill, S. M., Domenighetti, C., Schulze-Hentrich, J. M., Lesage, S., Brice, A., Corvol, J., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00704-3 · Cited by 19
Improving accuracy in noninvasive telemonitoring of progression of Parkinson'S Disease using two-step predictive model
Jain, S., & Shetty, S. D. (2016) · International Conference on Electrical, Electronics, Computer Engineering and their Applications (EECEA) · doi:10.1109/eecea.2016.7470774 · Cited by 19
Validity and Utility of a LRRK2 G2019S Mutation Test for the Diagnosis of Parkinson's Disease
Kay, D. M., Bird, T. D., Zabetian, C. P., Factor, S. A., Samii, A., Higgins, D. S., Nutt, J. G., Roberts, J. W., Griffith, A., Leis, B. C., et al. (2006) · Genetic Testing · doi:10.1089/gte.2006.10.221 · Cited by 19
Lost in translational biology: Understanding sex differences to inform studies of diseases of the nervous system
Pearse, R. V., & Young‐Pearse, T. L. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146352 · Cited by 22
Lipid profiling of Parkinson’s disease brain highlights disruption in Lysophosphatidylcholines, and triacylglycerol metabolism
Yılmaz, A., Ashrafi, N., Ashrafi, R., Akyol, S., Saiyed, N., Kerševičiūtė, I., Gabrielaitė, M., Gordevičius, J., & Graham, S. F. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01023-x · Cited by 25
Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease
Maraganore, D. M. (2011) · Journal of Movement Disorders · doi:10.14802/jmd.11001 · Cited by 18
1‐[2‐(4‐Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease
Chung, J. Y., Lee, J. W., Ryu, C. H., Min, H. K., Yoon, Y. J., Lim, M. J., & Park, C. H. (2015) · Journal of Neuroscience Research · doi:10.1002/jnr.23577 · Cited by 18
Investigating Neuroprotective Effects of Berberine on Mitochondrial Dysfunction and Autophagy Impairment in Parkinson’s Disease
Cha, H.-R., Kim, J.-S., Ryu, J., & Cho, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157342 · Cited by 18
The synaptic lipidome in health and disease
Vallés, A. S., & Barrantes, F. J. (2022) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2022.184033 · Cited by 16
Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease
Poulopoulos, M. (2009) · Core evidence · doi:10.2147/ce.s7031 · Cited by 17
Epidemiology of Parkinsonism
Rajput, A. H., Rajput, A. H., & Rajput, M. L. (2003) · CRC Press eBooks · doi:10.1201/9780203912164-6 · Cited by 17
Metabolic modeling links gut microbiota to metabolic markers of Parkinson’s disease
Hensen, T., & Thiele, I. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2554195 · Cited by 16
Impact of Parkinson's Disease on Complications, Readmission Rates, and Costs of Care following Primary Total Knee Arthroplasty
Marchand, K. B., Vakharia, R. M., Sodhi, N., Anis, H. K., Salem, H. S., Scuderi, G. R., Mont, M. A., & Roche, M. W. (2020) · The Journal of Knee Surgery · doi:10.1055/s-0040-1710546 · Cited by 16
Loudness Perception of Pure Tones in Parkinson's Disease
Abur, D., Lupiani, A. A., Hickox, A. E., Shinn‐Cunningham, B. G., & Stepp, C. E. (2018) · Journal of Speech Language and Hearing Research · doi:10.1044/2018_jslhr-h-17-0382 · Cited by 17
Parkinsonism in essential tremor cases: A clinicopathological study
Rajput, A. H., Rajput, E. F., Bocking, S. M., Auer, R. N., & Rajput, A. H. (2019) · Movement Disorders · doi:10.1002/mds.27729 · Cited by 16
Diagnosing Parkinson by Using Deep Autoencoder Neural Network
Köse, U., Deperlioğlu, Ö., Alzubi, J. A. A., & Pătruţ, B. (2020) · Studies in computational intelligence · doi:10.1007/978-981-15-6325-6_5 · Cited by 16

Authors: Elbaz, A., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., & Rocca, W. A.
Affiliations: Mayo Clinic (US)
Corresponding author: Rocca, Walter A
ORCID: Elbaz, Alexis
Bower, James H
Maraganore, Demetrius M
McDonnell, Shannon K
Ahlskog, J.Eric
Schaid, Daniel J
Rocca, Walter A
Venue: Journal of Clinical Epidemiology
Publisher: Elsevier BV
Published: 2002-01
Volume: 55
Issue: 1
Pages: 25-31
ISSN: 0895-4356 (ISSN-L)
DOI: 10.1016/s0895-4356(01)00425-5
OpenAlex: W2013713870
Cited by: 377
References: 21
Citations by year: 2026: 6 · 2025: 15 · 2024: 21 · 2023: 14 · 2022: 20 · 2021: 16 · 2020: 21 · 2019: 25 · 2018: 32 · 2017: 18 · 2016: 23 · 2015: 19 · 2014: 21 · 2013: 10 · 2012: 12
FWCI: 5.31
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Clinical Epidemiology (publishedVersion)
PubMed (publishedVersion)
Funders: Institut National de la Santé et de la Recherche Médicale
National Institutes of Health
National Institute of Neurological Disorders and Stroke (R01NS033978, NS33978)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR030582, AR30582)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Parkinson's disease, parkinsonism, lifetime risk, cumulative incidence, competing risk of death, incidence rates, mortality rates, sex differences, Olmsted County, Minnesota
MeSH terms: Adult, Aged, Female, Humans, Male, Middle Aged, Minnesota, Parkinson Disease, Risk Factors, Life Tables, Incidence, Age Distribution, Sex Distribution, Parkinsonian Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Risk tables for parkinsonism and Parkinson’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks